Baltimore Oral Epidemiology, Disease Effects, and HIV Evaluation Study (BEEHIVE)

巴尔的摩口腔流行病学、疾病影响和 HIV 评估研究 (BEEHIVE)

基本信息

  • 批准号:
    10668433
  • 负责人:
  • 金额:
    $ 91.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-08-01 至 2025-07-31
  • 项目状态:
    未结题

项目摘要

Since the advent of antiretroviral therapy (ART), the life expectancy of persons living with HIV (PLWH) has steadily increased in the United States. PLWH are now more likely to develop co-morbid age-related non- communicable diseases (NCDs) than are similarly-aged HIV-uninfected persons, and the morbidity and mortality of NCD and age-related conditions is paramount. The age-adjusted rates of multiple NCDs are higher among PLWH than among persons who are HIV negative. In addition, PLWH experience higher prevalence and severity of oral diseases, particularly related to the periodontium, although the factors that explain these disparities remain unclear. For example, is HIV-related immune suppression or viremia primarily responsible for these differences? Are lifestyle factors and access to dental care important determinants? Is the microbiome signature in PLWH unique and does it change over time? Since 1988, the AIDS Linked to the Intravenous Experience (ALIVE) study has successfully followed a lower-income, predominantly African American population of HIV-infected and at-risk persons with a history of injecting drugs (PWID) in a community-based cohort in Baltimore. Over three decades, ALIVE has characterized risk factors of incident HIV and progression to AIDS or death, described patterns of risk behaviors, identified barriers to optimal HIV care, and provided important insights into the natural and treated course of HIV among PWID. In recent years, ALIVE has transitioned to exploring the impact of aging with HIV, focusing on phenotypes and organ-specific non-communicable diseases (NCD) (e.g., liver, lung, cardiovascular, bone, kidney, neurocognitive and metabolic NCDs). The proposed project leverages the ALIVE platform to focus on the combined effects of HIV and NCDs on oral health at the health care-seeking, clinical, and microbiological levels. The specific aims of the proposed project are to: 1) determine to what extent HIV status influences access to and utilization of oral health care services; 2) determine to what extent HIV status affects self-reported and clinical oral health status; 3) determine to what extent HIV status influences the progression of periodontitis; and 4) determine to what extent HIV status impacts the periodontitis-associated oral microbiome signature. The first three specific aims include sub-aims that define the extent to which comorbid NCDs act as effect modifiers. For specific aim 4, one sub-aim describes the extent to which HIV influences the oral microbiome and a second sub-aim defines how longitudinal changes in the oral microbiome signature affect periodontitis progression. To achieve these aims, we build upon biannual ALIVE study visits with interview, clinical examination, and biospecimen components, supplemented by medical record review and registry linkages. The key impact of these aims is to illuminate social and individual-level mechanisms, identify modifiable risk factors, and produce novel insights to inform efficient and targeted oral health interventions for PLWH in Baltimore and nationally.
自从抗逆转录病毒疗法(ART)问世以来,艾滋病毒感染者的预期寿命已经缩短

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gregory D Kirk其他文献

Risk of anal cancer in HIV-infected patients and HIV-uninfected controls in North America
  • DOI:
    10.1186/1750-9378-5-s1-a70
  • 发表时间:
    2010-10-11
  • 期刊:
  • 影响因子:
    2.800
  • 作者:
    Michael J Silverberg;Bryan Lau;Yuezhou Jing;Gypsyamber D'Souza;Eric A Engels;John Gill;James J Goedert;Gregory D Kirk;Amy Justice;Robert Dubrow
  • 通讯作者:
    Robert Dubrow
Association of Primary Care Engagement with Initiation and Continuation of Medication Treatment for Opioid Use Disorder Among Persons with a History of Injection Drug Use
初级保健参与与有注射吸毒史的人开始和继续阿片类药物使用障碍药物治疗的关系
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    D. Sosnowski;K. Feder;Becky L. Genberg;S. Mehta;Gregory D Kirk
  • 通讯作者:
    Gregory D Kirk
Association of immunosuppression and HIV viremia with anal cancer risk in persons living with HIV in the United States and Canada.
美国和加拿大艾滋病毒感染者的免疫抑制和艾滋病毒病毒血症与肛门癌风险的关联。
  • DOI:
  • 发表时间:
    2019
  • 期刊:
  • 影响因子:
    11.8
  • 作者:
    R. Hernández;L. Qin;Haiqun Lin;W. Leyden;Romain S. Neugebauer;K. Althoff;N. Hessol;Chad J. Achenbach;J. T. Brooks;M. Gill;S. Grover;M. Horberg;Jun Li;W. C. Mathews;Á. Mayor;P. Patel;Charles S Rabkin;A. Rachlis;Amy C. Justice;Richard D. Moore;Eric A. Engels;M. Silverberg;R. Dubrow;Constance A. Benson;Ronald J. Bosch;Gregory D Kirk;Kenneth H. Mayer;C. Grasso;Robert S. Hogg;P. Richard Harrigan;J. Montaner;B. Yip;Julia Zhu;K. Salters;Karyn Gabler;K. Buchacz;Jun Li;K. Gebo;Richard D. Moore;B. Rodriguez;M. Horberg;M. Silverberg;Jennifer E. Thorne;Charles S Rabkin;Joseph B. Margolick;Lisa P. Jacobson;Gypsyamber D'Souza;M. Klein;A. Kroch;Ann N. Burchell;Adrian Betts;Joanne D. Lindsay;R. Hunter;Á. Mayor;M. John Gill;S. Deeks;Jeffrey N. Martin;J. T. Brooks;M. Saag;M. Mugavero;James Willig;W. C. Mathews;Joseph J Eron;S. Napravnik;M. Kitahata;Heidi M Crane;D. Drozd;Timothy R. Sterling;David Haas;Peter F. Rebeiro;M. Turner;Amy C. Justice;R. Dubrow;David A. Fiellin;S. Gange;K. Anastos;K. Althoff;R. Mckaig;Aimee M. Freeman;Stephen E. Van Rompaey;Liz Morton;J. McReynolds;William Lober;Jennifer S. Lee;Bin You;B. Hogan;Jinbing Zhang;Jerry Jing;E. Humes;Sally B Coburn
  • 通讯作者:
    Sally B Coburn

Gregory D Kirk的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gregory D Kirk', 18)}}的其他基金

Research Supplements to Promote Diversity in Health-Related Research
促进健康相关研究多样性的研究补充
  • 批准号:
    10643214
  • 财政年份:
    2020
  • 资助金额:
    $ 91.04万
  • 项目类别:
H2A Developmental Core
H2A 发展核心
  • 批准号:
    10084614
  • 财政年份:
    2020
  • 资助金额:
    $ 91.04万
  • 项目类别:
HIV and HCC in Africa: The H2A Consortium
非洲的艾滋病毒和肝癌:H2A 联盟
  • 批准号:
    10471411
  • 财政年份:
    2020
  • 资助金额:
    $ 91.04万
  • 项目类别:
Antiviral treatment as prevention for HBV- and HBV/HIV-associated hepatocellular carcinoma
抗病毒治疗预防 HBV 和 HBV/HIV 相关肝细胞癌
  • 批准号:
    10689163
  • 财政年份:
    2020
  • 资助金额:
    $ 91.04万
  • 项目类别:
H2A Admin Core
H2A 管理核心
  • 批准号:
    10471412
  • 财政年份:
    2020
  • 资助金额:
    $ 91.04万
  • 项目类别:
H2A Admin Core
H2A 管理核心
  • 批准号:
    10084612
  • 财政年份:
    2020
  • 资助金额:
    $ 91.04万
  • 项目类别:
Antiviral treatment as prevention for HBV- and HBV/HIV-associated hepatocellular carcinoma
抗病毒治疗预防 HBV 和 HBV/HIV 相关肝细胞癌
  • 批准号:
    10259886
  • 财政年份:
    2020
  • 资助金额:
    $ 91.04万
  • 项目类别:
H2A Developmental Core
H2A 发展核心
  • 批准号:
    10471414
  • 财政年份:
    2020
  • 资助金额:
    $ 91.04万
  • 项目类别:
Baltimore Oral Epidemiology, Disease Effects, and HIV Evaluation Study (BEEHIVE)
巴尔的摩口腔流行病学、疾病影响和 HIV 评估研究 (BEEHIVE)
  • 批准号:
    10223266
  • 财政年份:
    2020
  • 资助金额:
    $ 91.04万
  • 项目类别:
Study of HIV Infection in the Etiology of Lung Disease (SHIELD) AIR: Air Pollution Impact on Respiratory Health in HIV
HIV 感染与肺部疾病病因学研究 (SHIELD) 空气:空气污染对 HIV 呼吸系统健康的影响
  • 批准号:
    10664953
  • 财政年份:
    2020
  • 资助金额:
    $ 91.04万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 91.04万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 91.04万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 91.04万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 91.04万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 91.04万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 91.04万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 91.04万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 91.04万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 91.04万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 91.04万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了